Walgreens (NYSE: WAG) (Nasdaq: WAG) had December sales of $7.20 billion, an increase of 7.2 percent from $6.72 billion for the same month in fiscal 2013. Total front-end sales increased 4.0 percent compared with the same month in fiscal 2013, while comparable store front-end sales increased 2.5 percent. Customer traffic in comparable stores decreased 1.3 percent while basket size increased 3.8 percent. Prescriptions filled at comparable stores increased by 5.3 percent in December and increased 2.4 percent on a calendar day-shift adjusted basis. December 2013 had one additional Tuesday and one fewer Saturday compared with December 2012. These calendar shifts positively impacted prescriptions filled at comparable stores by 2.9 percentage points. Prescriptions filled at comparable stores were negatively impacted by 0.4 percentage point due to fewer flu shots in the month versus last year and were negatively impacted by 0.8 percentage point due to the lower incidence of flu in December 2013. December pharmacy sales increased by 10.2 percent, while comparable store pharmacy sales increased 9.0 percent and increased by a calendar day-shift adjusted 6.1 percent. Calendar day shifts positively impacted pharmacy sales in comparable stores by 2.9 percentage points. Calendar day-shift adjusted comparable store pharmacy sales were negatively impacted by 1.2 percentage points due to generic drug introductions in the last 12 months, and were negatively impacted by 0.2 percentage point due to fewer flu shots in December versus last year. The lower incidence of flu negatively impacted pharmacy sales by 0.4 percentage point. Pharmacy sales accounted for 58.3 percent of total sales for the month. Flu shots administered at pharmacies and clinics season to date were more than 6.7 million versus nearly 5.5 million last year. Sales in comparable stores increased by 6.1 percent in December. Calendar day shifts positively impacted total comparable sales by 1.7 percentage points, while generic drug introductions in the last 12 months negatively impacted total comparable sales by 0.7 percentage point.